吡侖帕奈為第3代新型廣譜抗癲癇藥物，其血藥濃度或藥物暴露水平與其臨床療效、不良反應(yīng)密切相關(guān)，因此建議進(jìn)行治療藥物監(jiān)測。圍繞吡侖帕奈的治療藥物監(jiān)測開展其有效血藥濃度參考范圍、血藥濃度影響因素研究已成為實(shí)現(xiàn)吡侖帕奈個(gè)體化精準(zhǔn)用藥的關(guān)鍵。對吡侖帕奈治療藥物監(jiān)測的研究報(bào)道進(jìn)行了分析，旨在為吡侖帕奈在臨床上的個(gè)體化精準(zhǔn)用藥提供參考。

Perampanel is a third-generation novel broad-spectrum antiepileptic drug, and its blood drug concentration or drug exposure level is closely related to its clinical efficacy and adverse reactions. Therefore, it is recommended to carry on therapeutic drug monitoring. Studies on the reference range of effective blood drug concentration and influencing factors of blood drug concentration have been carried out around the therapeutic drug monitoring for perampanel, which have become the key to realize individualized precise use of perampanel. This article analyzes the research reports on the therapeutic drug monitoring for perampanel, aiming to provide reference for individualized precision use of perampanel in clinical practice.

R971

安徽省藥師協(xié)會藥師隊(duì)伍建設(shè)“扶持計(jì)劃”治療藥物監(jiān)測與個(gè)體化用藥研究專項(xiàng)（SPSG2023001004）；安徽醫(yī)科大學(xué)校科研基金項(xiàng)目（2022xkj100）；六安市科技計(jì)劃項(xiàng)目（2022lakj005）